NASDAQ:OTIC - Otonomy Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.10
  • Forecasted Upside: 216.41 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.56
▲ +0.06 (2.40%)
1 month | 3 months | 12 months
Get New Otonomy Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OTIC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OTIC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$8.10
▲ +216.41% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Otonomy in the last 3 months. The average price target is $8.10, with a high forecast of $11.00 and a low forecast of $5.00. The average price target represents a 216.41% upside from the last price of $2.56.
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Otonomy. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/15/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2021HC WainwrightLower Price TargetBuy$10.00 ➝ $5.50Low
i
2/23/2021HC WainwrightLower Price TargetBuy$10.00 ➝ $5.50Low
i
2/22/2021Piper SandlerLower Price Target$10.00 ➝ $5.00N/A
i
12/18/2020HC WainwrightBoost Price TargetPositive ➝ Buy$9.00 ➝ $10.00High
i
Rating by Oren Livnat at HC Wainwright
11/22/2020OppenheimerInitiated CoverageBuy$11.00Medium
i
Rating by Francois Brisebois at Oppenheimer Holdings Inc.
8/17/2020Cantor FitzgeraldReiterated RatingOverweight$11.00High
i
8/6/2020HC WainwrightReiterated RatingBuy$9.00Low
i
Rating by Oren Livnat at HC Wainwright
7/7/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$9.00 ➝ $11.00High
i
7/7/2020HC WainwrightBoost Price TargetPositive ➝ Buy$8.00 ➝ $9.00High
i
Rating by Oren Livnat at HC Wainwright
7/6/2020OppenheimerReiterated RatingBuy$8.00High
i
Rating by Francois Brisebois at Oppenheimer Holdings Inc.
6/16/2020HC WainwrightReiterated RatingBuy$8.00Low
i
Rating by Oren Livnat at HC Wainwright
6/16/2020Cantor FitzgeraldBoost Price TargetOverweight$3.00 ➝ $9.00High
i
6/5/2020HC WainwrightReiterated RatingBuy ➝ Market Perform$8.00Medium
i
5/29/2020OppenheimerInitiated CoverageBuy$8.00High
i
Rating by Francois Brisebois at Oppenheimer Holdings Inc.
5/29/2020Craig HallumInitiated CoverageBuy$8.00High
i
Rating by Francois Brisebois at Craig Hallum
12/24/2019OppenheimerInitiated CoverageOutperform$8.00High
i
11/6/2019HC WainwrightReiterated RatingBuy$8.00Medium
i
Rating by O. Livnat at HC Wainwright
8/29/2019HC WainwrightInitiated CoverageBuy$8.00High
i
Rating by O. Livnat at HC Wainwright
3/5/2019Piper Jaffray CompaniesReiterated RatingBuyLow
i
Rating by Tyler Van Buren at Piper Jaffray Companies
3/4/2019Cantor FitzgeraldReiterated RatingBuy$5.00High
i
11/14/2018Cantor FitzgeraldInitiated CoverageOverweight$9.00Medium
i
8/14/2018SunTrust BanksLower Price TargetBuy$10.00Low
i
3/19/2018JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
i
3/12/2018Piper Jaffray CompaniesUpgradeNeutral ➝ OverweightMedium
i
11/10/2017Piper Jaffray CompaniesReiterated RatingHold$8.00N/A
i
8/31/2017CowenReiterated RatingOutperform$55.00 ➝ $9.00Low
i
8/31/2017SunTrust BanksReiterated RatingBuy$45.00 ➝ $15.00High
i
8/30/2017Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$32.00 ➝ $8.00High
i
8/30/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$28.00 ➝ $8.00High
i
8/23/2017CowenReiterated RatingOutperform$55.00Medium
i
8/15/2017JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$28.00High
i
6/30/2017Piper Jaffray CompaniesReiterated RatingOverweight$32.00Low
i
6/2/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$32.00Medium
i
11/2/2016Piper Jaffray CompaniesReiterated RatingBuy$32.00N/A
i
Rating by joshua schimmer at Piper Jaffray Companies
8/15/2016Piper Jaffray CompaniesReiterated RatingOverweight$32.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
8/8/2016Piper Jaffray CompaniesReiterated RatingOverweight$42.00 ➝ $32.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
5/26/2016WallachBeth CapitalInitiated CoverageBuy$29.00N/A
i
5/22/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
5/10/2016Piper Jaffray CompaniesReiterated RatingOverweight$46.00 ➝ $42.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
4/18/2016Piper Jaffray CompaniesReiterated RatingBuy$46.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
(Data available from 3/9/2016 forward)
Otonomy logo
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone that has completed Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed Phase I/II clinical trial to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $2.56
$2.45
$2.60

50 Day Range

MA: $4.40
$2.50
$5.63

52 Week Range

Now: $2.56
$1.53
$6.98

Volume

539,885 shs

Average Volume

1,389,720 shs

Market Capitalization

$123.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Otonomy?

The following sell-side analysts have issued research reports on Otonomy in the last twelve months: Cantor Fitzgerald, Craig Hallum, HC Wainwright, Oppenheimer Holdings Inc., Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for OTIC.

What is the current price target for Otonomy?

5 Wall Street analysts have set twelve-month price targets for Otonomy in the last year. Their average twelve-month price target is $8.10, suggesting a possible upside of 216.4%. Oppenheimer Holdings Inc. has the highest price target set, predicting OTIC will reach $11.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $5.00 for Otonomy in the next year.
View the latest price targets for OTIC.

What is the current consensus analyst rating for Otonomy?

Otonomy currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OTIC will outperform the market and that investors should add to their positions of Otonomy.
View the latest ratings for OTIC.

What other companies compete with Otonomy?

How do I contact Otonomy's investor relations team?

Otonomy's physical mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company's listed phone number is 619-323-2200 and its investor relations email address is [email protected] The official website for Otonomy is www.otonomy.com.